CARACO PHARMACEUTICAL LABORATORIES LTD 4/A

Accession 0001169232-06-003044

CIK 0000887708operating

Filed

Jul 12, 8:00 PM ET

Accepted

Jul 13, 12:24 PM ET

Size

29.5 KB

Accession

0001169232-06-003044

Form 4/AAmended

Period: 2006-06-01

Director(Non-Executive) Chairman

Transactions

Other
Series B. Preferred Stock
2006-06-01+544,000→ 11,424,000 total(indirect: See Footnote)
Exercise: $0.00From: 2009-06-01→ Common Stock (544,000 underlying)

10% Owner

Transactions

Other
Series B. Preferred Stock
2006-06-01+544,000→ 11,424,000 total(indirect: See Footnote)
Exercise: $0.00From: 2009-06-01→ Common Stock (544,000 underlying)

10% Owner

Transactions

Other
Series B. Preferred Stock
2006-06-01+544,000→ 11,424,000 total(indirect: See Footnote)
Exercise: $0.00From: 2009-06-01→ Common Stock (544,000 underlying)

Footnotes (4)

[F1]The Series B preferred shares are convertible into common stock after three years (or immediately upon a change in control) on a one-to-one basis.
[F2]Sun Pharma Global, Inc. ("Sun Global") earns 544,000 shares of Series B Preferred Stock for each technology transfer to Caraco of a generic drug by Sun Global when such drug passes its bioequivalency studies. In the event of the dissolution of Caraco, such shares have a preference equal to the value attributed to them on the dates on which they were earned. The value attributed as of June 1, 2006 was $8.05.
[F3]The shares of Series B Preferred Stock remain outstanding until such time as they are converted into Common Stock.
[F4]These shares are owned directly by Sun Global, Inc., which is a wholly-owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun"). Dilip S. Shanghvi is the controlling shareholder of Sun.

Documents

4 files

CARACO PHARMACEUTICAL LABORATORIES LTD

CIK 0000887708

Entity typeoperating

IncorporatedMI